Claims for Patent: 7,789,841

Summary for Patent: 7,789,841

Title:	Method and apparatus for connective tissue treatment
Abstract:	The invention relates to methods and apparatus for therapeutically treating connective tissue or increasing vascularization in tissue using ultrasound. More particularly, the present invention relates to methods and apparatus which use ultrasound to stimulate growth or healing, or to treating pathologies, of connective tissue, or to increase vascularization in ischaemic or grafted tissue using ultrasound.
Inventor(s):	Huckle; James William (Northallerton, GB), Carter; Andrew J. (Acton, MA), Cotton; Nicholas J. (Westboro, MA), Walsh; William R. (Maroubra, AU), Scarborough; Nelson (Andover, MA), Talish; Roger (Hillsborough, NJ)
Assignee:	Exogen, Inc. (Piscataway, NJ)
Application Number:	10/131,784
Patent Claims:	1. A method for stimulating growth or healing, or treating pathologies, of connective tissue in mammals in need thereof, comprising: subjecting the affected connective tissue selected from the group consisting of cartilage in one or more natural joints of the mammal, ligaments, tendons, fascia, and combinations thereof to noninvasive, low intensity pulsed ultrasound with a substantially single frequency between about 1 and about 2 MHz, a pulse width of between about 10 and about 2,000 microseconds, a repetition frequency of about 0.10 to about 10 KHz, and a duration sufficient to stimulate growth, healing, or repair of the connective tissue. 2. The method of claim 1, wherein the low intensity ultrasound has a frequency of around 1.5 MHz. 3. The method of claim 1, wherein the pulse width is about 200 microseconds. 4. The method of claim 1, wherein the repetition frequency is about 1 KHz. 5. The method of claim 1, wherein the connective tissue comprises tissue that has undergone or is undergoing degeneration as the result of osteoarthritis, tendonosis, or tendonitis, or a combination thereof. 6. The method of claim 5, wherein healing is stimulated without surgical repair or modification of the tissue. 7. The method of claim 1, wherein the connective tissue undergoing treatment has been subjected to surgery on or near the connective tissue. 8. The method of claim 7, wherein the surgery comprises repair of flexor or extensor tendons. 9. The method of claim 7, wherein the surgery comprises surgical transfer of a ligament or tendon or a ligament or tendon weave. 10. The method of claim 7, wherein the surgery comprises implantation of a scaffold capable of supporting tissue repair or regrowth. 11. The method of claim 10, wherein the scaffold comprises a material having a structure sufficiently porous to allow cell infiltration, and having a surface sufficient to allow cell adhesion and growth. 12. The method of claim 7, wherein the surgery comprises repair of a fibrocartilage. 13. The method of claim 12, wherein the fibrocartilage is selected from the group consisting of damaged lateral or medial meniscus, mandibular meniscus, spinal disc cartilage, and rib cartilage. 14. The method of claim 1, wherein the connective tissue undergoing treatment comprises one or more ligaments. 15. The method of claim 14, wherein at least one of the ligaments is located in the human knee. 16. The method of claim 15, wherein the ligaments include the anterior cruciate ligament or posterior cruciate ligament. 17. The method of claim 15, wherein the one or more ligaments include a genual ligament or a meniscofemoral ligament. 18. The method of claim 14, wherein the one or more ligaments include a lateral or collateral ligament. 19. The method of claim 1, wherein the connective tissue undergoing treatment comprises one or more tendons. 20. The method of claim 19, wherein at least one of the tendons is located in the human knee. 21. The method of claim 20, wherein the tendon is one or more of the tendon of quadriceps, gracilis tendon, sartorius tendon, semitendinosis tendon, popliteus tendon, or adductor magnus tendon. 22. The method of claim 19, wherein the tendon is in the human shoulder. 23. The method of claim 22, wherein the tendon is the supraspinatus tendon. 24. The method of claim 1, wherein the connective tissue is a spinal disc with a degenerative disease. 25. The method of claim 1, wherein the ultrasound is applied to connective tissue following a tissue shrinkage procedure. 26. The method of claim 25, wherein the tissue shrinkage procedure is selected from the group consisting of capsulorraphy and spinal disc shrinkage. 27. The method of claim 1, wherein the connective tissue pathology is tendonitis or tendonosis. 28. The method of claim 1, wherein the connective tissue has suffered an acute tear or chronic overuse injury. 29. The method of claim 1, wherein the connective tissue is located in the elbow joint. 30. The method of claim 29, wherein the pathology is tennis elbow. 31. The method of claim 1, wherein the connective tissue is located in the foot. 32. The method of claim 31, wherein the pathology is plantar fascitis. 33. The method of claim 1, wherein the connective tissue comprises fascia. 34. The method of claim 1, wherein the connective tissue undergoing treatment is located in the human knee. 35. The method of claim 34, wherein the connective tissue comprises the lateral or medial meniscus. 36. The method of claim 1, further comprising administering to the mammal a pharmacological agent. 37. The method of claim 36, wherein the pharmacological agent is a drug or growth factor. 38. The method of claim 36, wherein the growth factor is administered in sufficient dosage to increase the rate of repair, the quality of repair, or both. 39. The method of claim 36, wherein the growth factor is selected from the group consisting of the Transforming Growth Factor .beta. superfamily, Bone Morphogenetic Proteins, Cartilage Derived Morphogenic Proteins and Growth Differentiation Factors, angiogenic factors, platelet-derived cell growth factor (PD-LCGF), Platelet Derived Growth Factors (PDGF), Vascular Endothelial Growth Factor (VEGF), the Epidermal Growth Factor family, Transforming Growth Factor Alpha (TGF.alpha.), Platelet Derived Growth Factors, e.g. PDGF-A, PDGF-B, PDGF-BB, Fibroblast Growth Factors, e.g. BFGF, Hepatocyte Growth Factors (HGF), Insulin-like Growth Factors, Growth Hormones (GH), Interleukins, Connective Tissue Growth Factors (CTGF), Parathyroid Hormone Related Proteins (PTHrp), autologous growth factors, and mixtures of at least two of these materials. 40. The method of claim 1, wherein the ultrasound is generated by a plurality of ultrasonic transducers placed in the vicinity of the skin the tissue to be treated. 41. The method of claim 40, wherein the ultrasonic transducers emit ultrasound simultaneously or sequentially. 42. The method of claim 1, wherein the intensity of the ultrasound is less than 100 milliwatts/cm.sup.2. 43. The method of claim 1 wherein subjecting the affected connective tissue to the low intensity pulsed ultrasound stimulates healing, growth, or repair of the connective tissue substantially without applying thermal energy. 44. A method for stimulating connective tissue in mammals in need thereof, the method comprising: subjecting the affected connective tissue selected from the group consisting of cartilage in one or more natural joints of the mammal, ligaments, tendons, fascia, and combinations thereof to noninvasive, low intensity pulsed ultrasound with a substantially single frequency between about 1 and about 2 MHz, a pulse width of between about 10 and about 2,000 microseconds, and a repetition frequency of about 0.10 to about 10 KHz. 45. A method for stimulating connective tissue in mammals in need thereof, the method comprising: subjecting the affected connective tissue selected from the group consisting of cartilage in one or more natural joints of the mammal, ligaments, tendons, fascia, and combinations thereof to noninvasive, low intensity pulsed ultrasound with a substantially single frequency between about 1 and about 2 MHz, a pulse width of between about 100 and about 300 microseconds, and a repetition frequency of about 0.5 to about 2.5 KHz. 46. A method for stimulating connective tissue in mammals in need thereof, the method comprising: subjecting the affected connective tissue selected from the group consisting of cartilage in one or more natural joints of the mammal, ligaments, tendons, fascia, and combinations thereof to noninvasive, low intensity pulsed ultrasound with a substantially single frequency, a pulse width of between about 100 and about 300 microseconds, and a repetition frequency of about 0.5 to about 2.5 KHz.

Details for Patent 7,789,841

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2017-02-06